131 results about "Endometrioses" patented technology

The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.

A medicament for the preventive and / or therapeutic treatment of allergic diseases and / or endometriosis and / or hysteromyoma which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof:wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substitutents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

The present invention refers to a group of biomarkers and to non-invasive in vitro methods for the diagnosis or prognosis of endometriosis, as well as to a kit to perform said methods.

The present invention relates to markers of endometriosis which are differentially expressed in the endometrial cells of females with endometriosis compared to endometriosis-free females. The invention also relates to methods for determining likelihood of endometriosis in female subjects, to methods for grading endometriosis in females suffering from endometriosis and to methods for treating this disease. The invention is also concerned with polynucleotides, probes, primers and kits useful for reducing into practice the above-mentioned methods which are more rapid, non invasive, much less complicated and much less costly than laparoscopy.

The invention relates to methods and a kit for the diagnosis of endometriosis. More particularly, the invention relates to the measurement of endometrial leukocytes bearing CD16b and, optionally, other leukocyte or serous markers, for determining likelihood of suffering from endometriosis in a female subject.

The invention relates to newly discovered marker polypeptides associated with endometriosis. Compositions, kits, and methods for detecting, characterizing, preventing, and treating endometriosis are provided.

A method for treating a vaginal disease by applying a hydrolyzed product in a variety of ways including preferably intravaginal, as well as oral, rectal, or transcutaneous administration, inhalation, intravenous or intraperitoneal injection. The product is produced by providing at least one solid plant product reduced to small pieces and mixed with sugar and a biocompatible liquid for fermentation at a temperature of between 15 and 55 degrees C. until its acidity reaches the range of 300 to 900 Terner degrees. Alternatively, the product is prepared by mixing in predetermined amounts of sprouted grains, biocompatible liquid inoculated with at least one from a variety of non-pathogenic microorganisms, vegetables, fruits, berries, high protein products, herbs, sugar, and a chemical element such as potassium. The mixture is then fermented at a selected temperature for a specified length of time to reach high acidity and high concentration of products of bacterial metabolism. This invention relates to a hydrolyzed medium used for the prevention of and treatment for urogenital infections, cancer and endometriosis.

The invention relates to a drug for treating endometriosis, in particular to TCM (Traditional Chinese Medicine) oral solution for treating endometriosis, which is made by adopting plants and herbal medicine as raw materials. The invention adopts the technical scheme as follows: the TCM (Traditional Chinese Medicine) oral solution for treating endometriosis comprises following crude drugs according to the parts by weight: 3 to 12g of Radix Bupleuri, 3 to 8g of Radix Salviae Miltiorrhizae, 3 to 12g of Radix Angelicae Sinensis, 3 to 12g of Semen Persicae, 3 to 12g of Flos Carthami, 3 to 12g of Rhizoma Sparganii, 3 to 12g of Rhizoma Curcumae, 3 to 8g of Radix Glycyrrhizae 3 to 8, 3 to 12g of Radix Cyathulae, 5 to 15g of Radix Paeoniae Rubra and 3 to 8g of Rhizoma Chuanxiong. The TCM (Traditional Chinese Medicine) oral solution for treating endometrios is compounded to benefit mutually, and has the effects of promoting qi and blood flows, removing heat evil and toxic substances, eliminating stagnation and relieving pains, removing heat from blood and relieving swelling, relieving restlessness and tranquilizing the mind and alleviating constipation. The TCM is taken orally to achieve the functions of regulating the physiological functions, strengthening the body resistance to consolidate the constitution, adjusting endocrine disorders, enhancing immune function, keeping the balance of Yin and Yang and restoring dynamic balance of functions of the internal organs, so as to effectively treat endometriosis. The TCM (Traditional Chinese Medicine) oral solution for treating endometriosis has no adverse effect, is economical and can be made home with ease; and is applied to the treatment of pelvic diseases such as endometrial nodules or ovarian chocolate cyst.

A compound having the general formula: in which: R1 is a member selected from the group consisting of —OCH3, —SCH3, —N(CH3)2, —NHCH3, —CHO, —COCH3 and —CHOHCH3; R2 is a member selected from the group consisting of halogen, alkyl, acyl, hydroxy, alkoxy, acyloxy, alkyl carbonate, cypionyloxy, S-alkyl and S-acyl; R3 is a member selected from the group consisting of alkyl, hydroxy, alkoxy and acyloxy; R4 is a member selected from the group consisting of hydrogen and alkyl; and X is a member selected from the group consisting of ═O and ═N—OR5, wherein R5 is a member selected from the group consisting of hydrogen and alkyl. In addition to providing the compounds of Formula I, the present invention provides methods wherein the compounds of Formula I are advantageously used, inter alia, to antagonize endogenous progesterone; to induce menses; to treat endometriosis; to treat dysmenorrhea; to treat endocrine hormone-dependent tumors; to treat uterine fibroids; to inhibit uterine endometrial proliferation; to induce labor; and for contraception.

The present invention is one kind of medicine for treating endometriosis and its preparation process. The medicine is dispersant tablet comprising medicinal material megestrol acetate and corresponding supplementary material, and may be also prepared into other pharmaceutically acceptable forms, such as pill, common tablet, granule, oral liquid, etc. The medicine has obvious curative effect on endometriosis, stable quality, and other advantages.

The invention relates to a drug used for treating endometriosis. The drug is prepared by the following raw materials by weight: 2.80-3.20 parts of pieplant, 2.80-3.20 parts of turtle shell, and 1.30-1.70 parts of amber. The invention discloses a method of producing the drug used for treating endometriosis. The drug has the functions of dissipating blood stasis and purging the bowels, is mainly used for treating endometriosis the indications of which are dysmenorrhea, pelvic pain, straining feeling in anus, sore waist and constipation, dark tongue or with ecchymosis, thin tongue coating, thready pulse or pulse string small. Compared with the western medicine danazol, the invention has similar clinical curative effects but with fewer adverse effects and can be easily accepted by patients.

The present invention is directed to the neutralizing prolactin receptor antibody 002- H08, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.